ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia

Fungal Infection Clinical Trial

Official title:

ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00386997
• Other study ID #: GS-MC-131-0165
• Status: Terminated
• Phase: Phase 4
• First received: October 10, 2006
• Last updated: August 20, 2007
• Start date: November 2006
• Est. completion date: September 2007

Study information

• Verified date: August 2007
• Source: Gilead Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

Due to the poor outcome of patients with invasive fungal infections (IFI), a more effective prevention of these infections in such patients is wanted. These experiences in intensively treated elderly patients with acute leukemia are especially worrying.

This pilot study is designed to collect information on the safety (and efficacy) of an antifungal preventative therapy with an AmBisome® loading dose regimen of 7 mg/kg/week, in four weekly administrations, during the aplastic phase following the start of chemotherapy for acute lymphoblastic leukemia in elderly patients, which is a high risk period for severe fungal infections.

Description:

This is a multi-center, pilot, prospective, open label study. Approximately 20 patients will be recruited in 10 to 15 centers.

The patient group will be the following:

Elderly patients (≥ 55 years) with acute lymphoblastic leukemia undergoing chemotherapy with GMALL-Elderly 1/2003 protocol.

They will be treated with LAMB for four weeks after induction phase I. Patients will attend for full assessment until trial completion or withdrawal: there will be 3 assessment visits during the first week, 2 assessment visits during the second week, and 1 weekly assessment visit during the third and fourth week of the prophylaxis treatment (the first visit of each week being the infusion visit as well).

After the end of the prophylaxis period, patients will have 3 follow-up visits which will be scheduled at Weeks 6, 9, and 12.

Please note that no other systemic antifungal prophylaxis is allowed to be used concomitantly with AmBisome®.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: September 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients

• Patients with acute lymphoblastic leukemia (ALL) undergoing first induction chemotherapy within the GMALL-Elderly 1/2003 protocol

• Females of childbearing potential (less than 2 years post-menopausal) must be surgically incapable of pregnancy, or practicing an acceptable method of birth control with a negative pregnancy test (blood or urine) at baseline

• Understanding of the study's rationale and procedures documented in the patient's informed consent

• Ability and agreement to comply with all study requirements

• Patient willing to attend hospital appointments for each visit (infusions will be performed in hospital, under strict medical supervision).

Exclusion Criteria:

• Known hypersensitivity to amphotericin B or LAMB or any of its constituents, in particular known history of anaphylactic reaction to amphotericin B or LAMB or any of its constituents

• Signs or symptoms of IFI or previous proven or probable IFI in the medical history

• Evidence for pulmonary infiltrates in chest CT and/or x-ray of the chest (only when a chest CT/x-ray is done at baseline)

• Estimated creatinine clearance (ECC) = 60 mL/min (Cockcroft-Gault); in such cases the body surface adjusted Modification Diet in Renal Disease (MDRD) glomerular filtration rate (GFRMDRD) should be calculated. If the body surface adjusted GFRMDRD is above 60 mL/min, the patient can be included.

• Patient with moderate or severe liver disease as defined by AST, ALT or alkaline phosphatase (AP) > 5 times the upper limit of normal (ULN), or bilirubin > 3 times ULN

• Patients who are unlikely to survive more than 1 month

• Febrile patients (= 38.5°C)

• Patients who have received systemic antifungal therapy within 15 days prior to the inclusion

• Any severe co-morbidity other than the underlying hematological disease (ALL), which in the investigator's judgment may interfere with study evaluations or affect the patient's safety

• Patients previously included in this study

• Patients who have taken any investigational drug within the last 30 days prior to inclusion except drugs used according to the GMALL-Elderly/2003 protocol

• Patients who participate in another clinical trial except anti-cancer trials

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Fungal Infection
• Leukemia, Lymphoid
• Mycoses
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• liposomal amphotericin B (AmBisome®)

Locations

Country	Name	City	State
Germany	Gilead Sciences GmbH	Martinsried/Munich

Sponsors (1)

Lead Sponsor	Collaborator
Gilead Sciences

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To characterize the safety profile of a prophylactic antifungal LAMB treatment of
Primary	7 mg/kg, administered as a weekly intravenous infusion over two hours, during
Primary	induction treatment of acute lymphoblastic leukemia of elderly patients undergoing
Primary	chemotherapy with GMALL-Elderly 1/2003 protocol for four weeks
Secondary	Incidence and time to onset of possible, probable or proven IFI according to EORTC-MSG {3391} criteria within the 12 weeks following the initiation of prophylaxis treatment
Secondary	IFI free time as % of follow-up time
Secondary	The incidence of pulmonary infiltrates within 12 weeks following initiation of prophylaxis
Secondary	The need for additional systemic antifungal therapy within 12 weeks following initiation of prophylaxis
Secondary	The survival rate and incidence of mortality related to fungal infection at the end of prophylaxis treatment and within 12 weeks after prophylaxis treatment initiation